Drug Approval | August 09, 2025
Zydus receives final approval from USFDA for Prucalopride Tablets
Prucalopride is prescribed for chronic idiopathic constipation
Prucalopride is prescribed for chronic idiopathic constipation
This is the group’s first NoC approval in Canada
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
Allopurinol is used to prevent or lower high uric acid levels in the blood
Subscribe To Our Newsletter & Stay Updated
